PROJECT SUMMARY/ABSTRACT
Individuals with liver cirrhosis and alcoholic hepatitis often experience the complications of advanced liver
disease: ascites, hepatic encephalopathy, and gastrointestinal bleeding. These complications frequently lead
to hospitalizations, and after hospital discharge, disease complications can interact with medication errors and
poor provider communication, resulting in frequent early hospital readmissions. Outcomes during the
vulnerable post-discharge transition period could be improved through better transitional care (TC), focused on
optimizing treatment regimens, improving communication, and facilitating access to community and other
healthcare resources. TC addressing these issues has successfully improved outcomes in heart failure and
other conditions, but there are few data on TC programs in patients with advanced liver disease, who suffer
from unique clinical complications that can complicate TC treatment plans. To address this gap in our
healthcare delivery system, we have developed an advanced practice provider (APP)-led TC program for
patients with the complications of advanced liver disease: the Transitional Liver Clinic (TLC). In the TLC,
patients discharged from the hospital with complications of advanced liver disease are contacted by telephone
within two days of discharge, followed by a face-to-face or video telehealth visit with the APP within 7-14 days.
During this time, TLC providers reconcile and manage medications, provide education and linkage to
community resources, and facilitate necessary follow-up. This proposal aims to test the effect of the TLC on
hospital readmissions, quality of life, and patient satisfaction with care. The hypothesis is that the TLC will
improve patient outcomes across these domains. To achieve these aims, the TLC will be evaluated using a
pragmatic stepped-wedge randomized controlled trial comparing the TLC to usual care at four high-volume
tertiary care liver centers. Upon completion of the study, the investigators will have provided evidence for the
efficacy of TC in reducing acute healthcare utilization and in improving quality of life and patient satisfaction for
those with complications of advanced liver disease.